CA2166721A1 - Bicyclic tetrahydro pyrazolopyridines - Google Patents

Bicyclic tetrahydro pyrazolopyridines

Info

Publication number
CA2166721A1
CA2166721A1 CA2166721A CA2166721A CA2166721A1 CA 2166721 A1 CA2166721 A1 CA 2166721A1 CA 2166721 A CA2166721 A CA 2166721A CA 2166721 A CA2166721 A CA 2166721A CA 2166721 A1 CA2166721 A1 CA 2166721A1
Authority
CA
Canada
Prior art keywords
tnf
compounds
formula
production
pyrazolopyridines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2166721A
Other languages
French (fr)
Other versions
CA2166721C (en
Inventor
Allen Jacob Duplantier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Allen Jacob Duplantier
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allen Jacob Duplantier, Pfizer Inc. filed Critical Allen Jacob Duplantier
Publication of CA2166721A1 publication Critical patent/CA2166721A1/en
Application granted granted Critical
Publication of CA2166721C publication Critical patent/CA2166721C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Compounds of formula (I) wherein R1, R2, R3 and X
are as defined. The compounds of formula (I) and the pharmaceutically acceptable salts thereof are useful in inhibiting phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF) and in the treatment of asthma, arthritis, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis, dermatitis and other inflammatory diseases, AIDS, septic shock and other diseases involving the production of TNF.
CA002166721A 1993-07-06 1994-06-16 Bicyclic tetrahydro pyrazolopyridines Expired - Fee Related CA2166721C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8829293A 1993-07-06 1993-07-06
US08/088,292 1993-07-06
PCT/IB1994/000156 WO1995001980A1 (en) 1993-07-06 1994-06-16 Bicyclic tetrahydro pyrazolopyridines

Publications (2)

Publication Number Publication Date
CA2166721A1 true CA2166721A1 (en) 1995-01-19
CA2166721C CA2166721C (en) 1999-07-27

Family

ID=22210524

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002166721A Expired - Fee Related CA2166721C (en) 1993-07-06 1994-06-16 Bicyclic tetrahydro pyrazolopyridines

Country Status (20)

Country Link
EP (1) EP0707585A1 (en)
JP (1) JP2944048B2 (en)
KR (1) KR100228949B1 (en)
CN (1) CN1048015C (en)
AU (1) AU695301B2 (en)
BR (1) BR9406946A (en)
CA (1) CA2166721C (en)
CZ (1) CZ3696A3 (en)
EG (1) EG20513A (en)
FI (1) FI943208A (en)
HU (1) HUT74170A (en)
IL (1) IL110175A (en)
MX (1) MX9405132A (en)
NO (1) NO305029B1 (en)
NZ (1) NZ266525A (en)
PL (1) PL312426A1 (en)
RU (1) RU2131876C1 (en)
TW (1) TW316904B (en)
WO (1) WO1995001980A1 (en)
ZA (1) ZA944844B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU702105B2 (en) * 1994-10-20 1999-02-11 Pfizer Inc. Bicyclic tetrahydro pyrazolopyridines and their use as medicaments
DE69525978T2 (en) * 1995-06-06 2002-12-19 Pfizer TRICYCLIC 5,6-DIHYDRO-9H-PYRAZOLO (3,4-C) -1,2,4-TRIAZOLO (4,3-ALPHA) PYRIDINE
AP932A (en) * 1996-08-26 2001-02-02 Pfizer Tricyclic 5,6-dihydro-9H-pyrazolo (3,4c)-1,2,4,-triazolo (4,3-a) pyridines.
PL332187A1 (en) * 1996-09-04 1999-08-30 Pfizer Substitution derivatives of indazole and their application as inhibitors of phosphodiesterase (pde) of iv type and tumor necrosis factor (tnf)
US6858616B2 (en) 1998-12-23 2005-02-22 Bristol-Myers Squibb Pharma Company Nitrogen containing heterobicycles as factor Xa inhibitors
ES2232202T3 (en) * 1998-12-23 2005-05-16 Bristol-Myers Squibb Pharma Company HETEROBICICLES CONTAINING NITROGEN AS INHIBITORS OF THE XA FACTOR.
US6326495B2 (en) 1999-04-30 2001-12-04 Pfizer Inc. Process for preparing 8-cyclopentyl-6-ethyl-3-[substituted]-5,8-dihydro-4H-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein
PL200923B1 (en) 1999-08-21 2009-02-27 Nycomed Gmbh SYNERGISTIC COMBINATION OF PDE INHIBITORS AND ß₂ ADRENOCEPTOR AGONIST
TWI243055B (en) * 2000-04-13 2005-11-11 Nippon Zoki Pharmaceutical Co Pharmaceutical composition for use in treatment of dermatitis
PL213199B1 (en) * 2000-08-10 2013-01-31 Pharmacia Italia Spa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US6960595B2 (en) * 2001-03-23 2005-11-01 Bristol-Myers Squibb Pharma Company 5-6 to 5-7 Heterobicycles as factor Xa inhibitors
EP1379245A4 (en) 2001-04-18 2006-07-26 Bristol Myers Squibb Co 1, 4, 5, 6-tetrahydropyrazolo- 3, 4-c|-pyrid in-7-ones as factor xa inhibitors
WO2002085353A1 (en) 2001-04-18 2002-10-31 Bristol-Myers Squibb Company 1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-ones as factor xa inhibitors
JP4196678B2 (en) 2001-04-26 2008-12-17 味の素株式会社 Heterocyclic compounds
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
UA81453C2 (en) 2003-02-27 2008-01-10 Pyrazolopyridine derivates
US7135469B2 (en) * 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
CA2517487A1 (en) 2003-04-01 2004-10-14 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
DE102005031580A1 (en) * 2005-07-06 2007-01-11 Aicuris Gmbh & Co. Kg Substituted sulfolanylpyrazoles and their use
AR065804A1 (en) * 2007-03-23 2009-07-01 Smithkline Beecham Corp COMPOSITE OF INDOL CARBOXAMIDE, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND USE OF THIS COMPOUND TO PREPARE A MEDICINAL PRODUCT
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EA020466B1 (en) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011522828A (en) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2828346C (en) 2011-03-01 2021-01-26 Synergy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
AU2014218599C1 (en) 2013-02-25 2018-09-06 Bausch Health Ireland Limited Guanylate cyclase receptor agonists for use in colonic cleansing
JP2016514670A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase receptor agonists in combination with other drugs
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
KR102272746B1 (en) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 Ultra-pure agonists of guanylate cyclase c, method of making and using same
MX2016001714A (en) 2013-08-09 2016-10-03 Ardelyx Inc Compounds and methods for inhibiting phosphate transport.
CN110357888A (en) * 2018-04-09 2019-10-22 南京药捷安康生物科技有限公司 Heterocycle phosphodiesterase inhibitors and application thereof
JP2022533251A (en) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド Combinations to lower serum phosphate in patients

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1463883A (en) * 1964-09-08 1966-07-22 Ciba Geigy Process for the preparation of bicyclic triaza-compounds
US3365459A (en) * 1964-09-08 1968-01-23 Ciba Geigy Corp Certain tetrahydro pyrazolo-pyridine and pyrazolo-piperidine derivatives
US3340269A (en) * 1964-09-08 1967-09-05 Ciba Geigy Corp 1-substituted 4-acyl-2, 3-dioxo-piperidine
US5356897A (en) * 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines

Also Published As

Publication number Publication date
KR100228949B1 (en) 1999-11-01
AU695301B2 (en) 1998-08-13
ZA944844B (en) 1996-01-05
PL312426A1 (en) 1996-04-29
CA2166721C (en) 1999-07-27
IL110175A0 (en) 1994-10-07
CN1129940A (en) 1996-08-28
HU9503934D0 (en) 1996-03-28
FI943208A (en) 1995-01-07
HUT74170A (en) 1996-11-28
AU6805794A (en) 1995-02-06
WO1995001980A1 (en) 1995-01-19
NO960056D0 (en) 1996-01-05
EP0707585A1 (en) 1996-04-24
MX9405132A (en) 1995-01-31
JPH08507084A (en) 1996-07-30
BR9406946A (en) 1996-08-06
NO305029B1 (en) 1999-03-22
RU2131876C1 (en) 1999-06-20
TW316904B (en) 1997-10-01
NO960056L (en) 1996-01-05
CN1048015C (en) 2000-01-05
IL110175A (en) 2000-01-31
EG20513A (en) 1999-06-30
JP2944048B2 (en) 1999-08-30
CZ3696A3 (en) 1997-06-11
FI943208A0 (en) 1994-07-05
NZ266525A (en) 1997-10-24
KR960703852A (en) 1996-08-31

Similar Documents

Publication Publication Date Title
CA2166721A1 (en) Bicyclic tetrahydro pyrazolopyridines
MX9504422A (en) Bicyclic tetrahydro pyrazolopyridines.
CA2176506A1 (en) Substituted Oxindoles
CA2181175A1 (en) Dihydro Pyrazolopyrroles
CA2223624A1 (en) Tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-.alpha.]pyridines
WO2004024728A3 (en) Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
DE60004655T2 (en) PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE-RELATED DISEASES
CA2105302A1 (en) 1-azabicyclo¬3.2.2.|nonan-3-amine derivatives
WO2007040438A3 (en) Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
BG103725A (en) Nicotineamide derivatives
CA2086434A1 (en) Quinuclidine derivatives
GEP20033029B (en) Substituted 1,8-Naphthyridin-4(1H)-Ones as Phosphodiesterase 4 Inhibitors
WO2003089434A3 (en) IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF
CA2102179A1 (en) Quinuclidine derivatives
CA2269815A1 (en) Thienopyrimidines having pde v-inhibiting action
TW200500364A (en) Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
RU96103653A (en) Bicyclic Tetrahydropyrazolopyridines
DE60315674D1 (en) NEW IMIDAZOPYRIDINE AND ITS USE
NO980313L (en) N- (aroyl) glycine-hydroxamic acid derivatives and related compounds
MX2007000044A (en) Tetrahydroquinazolin-4(3h)-one-related and tetrahydropyrido[2,3-d ]pyrimidin-4(3h)-one-related compounds, compositions and methods for their use.
PL364427A1 (en) Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient
CA2223245A1 (en) Catechol diethers derivatives useful as pharmaceutical agents
NO20021083L (en) Pyrazolo [4,3-d] pyrimidines
CA2234239A1 (en) Indole carbamates as leukotriene antagonists
MY135776A (en) PYRAZOLO [3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed